# Artica Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artica-therapeutics-b-v

- Industry: Biotechnology
- Headquarters: Leiden, Netherlands
- Website: www.artica-tx.com
- Total disclosed funding: $12M
- Latest round: Seed (Nov 2, 2023)
- Investors on record: 4

## About

Based in Leiden, Netherlands, and founded in 2020 by CEO Tjeerd Barf, COO Arwin Ridder, and Prof. Ad IJzerman, Artica Therapeutics BV operates as a biotechnology company that researches and develops medications with small molecules for autoimmune and inflammatory symptoms. In November 2023, Artica Therapeutics BV raised USD 12 million in seed funding co-led by Thuja Capital and Seroba Life Sciences, with participation from InnovationQuarter and BioGeneration Ventures.

The company is developing novel therapies by leveraging covalent chemistry and label-free cellular-based screening approaches for patients suffering from severe autoimmune and inflammatory disorders.

Artica Therapeutics plans to use its proceeds from November 2023 funding to advance its small-molecule pipeline of novel covalent therapies to transform the treatment of autoimmune and inflammatory disorders.

## Funding rounds

- Seed, Nov 2, 2023, $12M — Seroba, BioGeneration Ventures, Thuja Capital, InnovationQuarter

## Investors

- Seroba (https://capitalatlas.ai/funds/seroba) — Seed
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Seed
- InnovationQuarter (https://capitalatlas.ai/funds/innovationquarter) — Seed